Economic pact outlines changes to drug pricing, investment commitments, and trade treatment between the two countries.
The Department of Commerce, the Office of the U.S. Trade Representative, and the Department of Health and Human Services (HHS) announced an agreement in principle with the United Kingdom addressing pharmaceutical pricing and market conditions. Under the U.S.–U.K. Economic Prosperity Deal (EPD), the two governments agreed on measures intended to adjust pricing practices in the U.K. market while supporting continued pharmaceutical investment in the U.S. The agreement includes commitments related to how new medicines are priced and reimbursed under the U.K.’s National Health Service.
“This agreement with the United Kingdom strengthens the global environment for innovative medicines and brings long-overdue balance to U.S.–U.K. pharmaceutical trade,“ said Health and Human Services Secretary Robert F. Kennedy, Jr. “President Trump showed real courage and leadership in demanding these reforms, and I thank him for delivering results that put Americans first.“
As part of the arrangement, the U.S. agreed to exempt U.K.-origin pharmaceuticals and related products from certain trade tariffs and to pause future investigations into U.K. pricing practices for the duration of the agreement. The agreement also includes provisions that maintain access to new medicines in both countries while supporting stable supply chains and manufacturing investment.
As the Lord Leads, Pray with Us…
- For Secretary Kennedy as he oversees the implementation of the pharmaceutical agreement.
- For U.S. Trade Representative Greer as he engages U.K. officials on trade and monitors agreement terms.
- For HHS and CMS officials as they assess how international pricing decisions affect patients and programs.
Sources: Department of Commerce
